abha@qu-consulting.com
+1-732-858-2299
Home
About
Practices
Open menu
Compliance
Regulatory Affairs
Science And Technology
Blogs
Contact
X
Contact Us
The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).
The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).